The company refused the FDA’s request and will continue shipping its therapy, Elevidys, to Duchenne patients who can still ...

An analysis from the Congressional Budget Office warns that cuts to the National Institutes of Health and FDA drug reviews could significantly reduce the number of new medications reaching the U.S.